Patel, md, discusses the fda approval of cemiplimab in cutaneous squamous cell carcinoma Cemiplimab is the first immunotherapy approved for adjuvant treatment in cscc, offering a new option for patients at high risk of recurrence. 1 libtayo was reviewed by fda under priority review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of. Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo This approval brings hope to adults with cscc who are at high risk of the cancer coming back, offering another way to lower the chances of recurrence This new approval is intended for patients who have.
OPEN
